Warning: The NCBI web site requires JavaScript to function. more...
Division of Rheumatology, Department of Internal Medicine, Eskisehir Osmangazi University, Eskiçsehir, Turkey.
The tumor necrosis factor-alpha (TNF-alpha) inhibitors are widely used in the treatment of some autoimmune disorders with promising results. However, their safety has been questioned with multiple postmarketing reports of increased risk for malignancies. The case of a patient with ankylosing spondylitis who developed cutaneous adenoid cystic carcinoma after three years of treatment with anti-TNF-alpha therapy is discussed.
Your browsing activity is empty.
Activity recording is turned off.
Turn recording back on